AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Capsaicin is commonly used topically in creams, ointments, and patches for the relief of various types of pain, including muscle pain, joint pain, neuropathic pain, and post-surgical pain. It works by desensitizing nerve receptors called TRPV1 receptors, which are involved in the transmission of pain signals. Capsaicin initially causes a burning sensation, followed by a period of decreased sensitivity to pain.
Arthritis: Topical capsaicin has been shown to be effective in relieving pain associated with osteoarthritis, rheumatoid arthritis, and other forms of arthritis. It can help reduce joint stiffness, improve mobility, and alleviate discomfort. Regular application of capsaicin cream or patches may provide long-term pain relief for individuals with arthritis.
Neuropathic Pain: Capsaicin has analgesic properties that may benefit individuals with neuropathic pain conditions such as diabetic neuropathy, postherpetic neuralgia (shingles), and peripheral neuropathy. Topical capsaicin can help reduce neuropathic pain symptoms, including burning, tingling, and shooting pains, by blocking pain signals transmitted by damaged nerves.
Digestive Health: Capsaicin may have gastroprotective effects and help promote digestive health. It has been shown to stimulate the production of gastric mucus, which forms a protective barrier in the stomach lining, reducing the risk of ulcers and gastritis. Capsaicin may also help increase gastric emptying and improve digestion by stimulating the release of digestive enzymes.
Weight Management: Capsaicin has been studied for its potential role in weight management and metabolism regulation. It can increase thermogenesis (heat production) and energy expenditure, leading to greater calorie burning and fat oxidation. Regular consumption of capsaicin-containing foods or supplements may help promote weight loss, particularly when combined with a balanced diet and exercise.
Cardiovascular Health: Some research suggests that capsaicin may have cardiovascular benefits, including lowering blood pressure and improving lipid profiles. Capsaicin may help dilate blood vessels, improve blood flow, and reduce inflammation, contributing to overall cardiovascular health and reducing the risk of heart disease and stroke.
Cancer Prevention: Capsaicin has been investigated for its potential anti-cancer properties. Studies have shown that capsaicin may inhibit the growth and proliferation of cancer cells, induce apoptosis (programmed cell death), and inhibit tumor angiogenesis (formation of new blood vessels to supply tumors). However, more research is needed to fully understand the mechanisms of action and potential therapeutic applications of capsaicin in cancer prevention and treatment.
Respiratory Health: Capsaicin may have bronchodilator and mucolytic properties that can benefit individuals with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and sinusitis. Capsaicin may help reduce airway inflammation, improve airflow, and promote the clearance of mucus from the respiratory tract, leading to symptom relief and improved respiratory function.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| Acne | 1.8 | 0.8 | 1.25 |
| ADHD | 2.7 | 0.4 | 5.75 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | -0.6 | |
| Allergies | 1.8 | 1.4 | 0.29 |
| Allergy to milk products | 0.7 | 1.4 | -1 |
| Alopecia (Hair Loss) | 0.6 | -0.6 | |
| Alzheimer's disease | 3.4 | 3.3 | 0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 2.2 | -0.16 |
| Ankylosing spondylitis | 0.9 | 0.8 | 0.13 |
| Anorexia Nervosa | 1.8 | 1 | 0.8 |
| Asthma | 2.9 | 0.2 | 13.5 |
| Atherosclerosis | 1 | 1.5 | -0.5 |
| Atrial fibrillation | 0.6 | 0.2 | 2 |
| Autism | 4.2 | 3.5 | 0.2 |
| benign prostatic hyperplasia | 0.3 | 0.3 | |
| Bipolar Disorder | 2.9 | 2.5 | 0.16 |
| Brain Trauma | 0.8 | 0.2 | 3 |
| Breast Cancer | 0.2 | 0.2 | |
| Carcinoma | 0.7 | 0.5 | 0.4 |
| Celiac Disease | 3.2 | 0.7 | 3.57 |
| Cerebral Palsy | 0.8 | 0.4 | 1 |
| Chronic Fatigue Syndrome | 2.3 | 0.6 | 2.83 |
| Chronic Kidney Disease | 1.9 | 0.2 | 8.5 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.2 | 0.5 |
| Chronic Urticaria (Hives) | 1.2 | 0.7 | 0.71 |
| Coagulation / Micro clot triggering bacteria | 0.5 | 0.2 | 1.5 |
| Colorectal Cancer | 1.3 | 0.7 | 0.86 |
| Constipation | 0.6 | 0.3 | 1 |
| Coronary artery disease | 0.2 | 0.5 | -1.5 |
| COVID-19 | 4.1 | 2.4 | 0.71 |
| Crohn's Disease | 4.3 | 3.5 | 0.23 |
| cystic fibrosis | 0.9 | 0.9 | |
| deep vein thrombosis | 0.5 | 0.5 | |
| Depression | 3.8 | 3.8 | 0 |
| Dermatomyositis | 1.3 | 1.3 | |
| Eczema | 0.7 | 0.8 | -0.14 |
| Endometriosis | 0.4 | 1.6 | -3 |
| Eosinophilic Esophagitis | 1.7 | 1.7 | |
| Epilepsy | 2.3 | 3.2 | -0.39 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.8 | 1 | -0.25 |
| Functional constipation / chronic idiopathic constipation | 1.9 | 2.6 | -0.37 |
| gallstone disease (gsd) | 0.6 | 0.7 | -0.17 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.6 | -0.2 |
| Glioblastoma | 0.9 | 0.9 | |
| Gout | 1.3 | 0.4 | 2.25 |
| Graves' disease | 1.7 | 0.2 | 7.5 |
| Halitosis | 0.2 | -0.2 | |
| Hashimoto's thyroiditis | 0.6 | 0.7 | -0.17 |
| Heart Failure | 0.2 | -0.2 | |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.2 | -0.2 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| hypercholesterolemia (High Cholesterol) | 1 | 0.2 | 4 |
| hyperglycemia | 1 | 0.9 | 0.11 |
| Hyperlipidemia (High Blood Fats) | 0.2 | 1.7 | -7.5 |
| hypersomnia | 0.2 | 0.2 | 0 |
| hypertension (High Blood Pressure | 1.9 | 2 | -0.05 |
| Hypothyroidism | 1.1 | 0.5 | 1.2 |
| Hypoxia | 0.4 | -0.4 | |
| IgA nephropathy (IgAN) | 0.2 | 0.6 | -2 |
| Inflammatory Bowel Disease | 2.9 | 1.9 | 0.53 |
| Insomnia | 1.5 | 1.5 | |
| Intelligence | 0.4 | 0.5 | -0.25 |
| Intracranial aneurysms | 0.6 | 1.5 | -1.5 |
| Irritable Bowel Syndrome | 2.3 | 1.9 | 0.21 |
| Juvenile idiopathic arthritis | 1.1 | 1.1 | |
| Liver Cirrhosis | 1.5 | 1.5 | 0 |
| Long COVID | 4.3 | 5 | -0.16 |
| Low bone mineral density | 0.5 | 0.5 | |
| Lung Cancer | 1.5 | 0.2 | 6.5 |
| ME/CFS with IBS | 0.8 | 0.8 | |
| ME/CFS without IBS | 0.4 | -0.4 | |
| Metabolic Syndrome | 4.6 | 4.2 | 0.1 |
| Mood Disorders | 4.5 | 5.7 | -0.27 |
| multiple chemical sensitivity [MCS] | 0.2 | 0.4 | -1 |
| Multiple Sclerosis | 2.5 | 3.3 | -0.32 |
| Multiple system atrophy (MSA) | 0.2 | 0.8 | -3 |
| Neuropathy (all types) | 0.7 | 1.9 | -1.71 |
| neuropsychiatric disorders (PANDAS, PANS) | 2.3 | 2.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 1 | 1.3 |
| Obesity | 5.2 | 3.3 | 0.58 |
| obsessive-compulsive disorder | 1.8 | 0.8 | 1.25 |
| Osteoarthritis | 1.9 | 1.9 | |
| Osteoporosis | 2.5 | 1 | 1.5 |
| pancreatic cancer | 0.3 | -0.3 | |
| Parkinson's Disease | 2.6 | 3 | -0.15 |
| Polycystic ovary syndrome | 1 | 0.4 | 1.5 |
| Premenstrual dysphoric disorder | 0.7 | -0.7 | |
| primary biliary cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0.7 | 3 | -3.29 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.4 | 2.3 | -0.64 |
| Rosacea | 1.3 | 0.2 | 5.5 |
| Schizophrenia | 2.1 | 2.1 | 0 |
| scoliosis | 0.2 | 0.3 | -0.5 |
| Sjögren syndrome | 1.6 | 1.4 | 0.14 |
| Sleep Apnea | 0.6 | 1.4 | -1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.3 | 1 |
| Stress / posttraumatic stress disorder | 2.6 | 0.4 | 5.5 |
| Systemic Lupus Erythematosus | 2.7 | 1.1 | 1.45 |
| Tic Disorder | 1.1 | -1.1 | |
| Tourette syndrome | 0.3 | 0.4 | -0.33 |
| Type 1 Diabetes | 1.4 | 1.3 | 0.08 |
| Type 2 Diabetes | 3.7 | 4.2 | -0.14 |
| Ulcerative colitis | 3.9 | 2.8 | 0.39 |
| Unhealthy Ageing | 1.3 | 1.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.